eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | non-alcoholic fatty liver disease |
| Comorbidity | C0011860|type 2 diabetes mellitus |
| Sentences | 36 |
| PubMedID- 26573193 | Objective: to explore the relationship between socioeconomic status (ses) and non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 26011302 | Background: nonalcoholic fatty liver disease (nafld) is associated with obesity, type 2 diabetes mellitus, and dyslipidemia. |
| PubMedID- 25966055 | Role of apn and tnf-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. |
| PubMedID- 25885947 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 21554270 | Role of type 2 diabetes mellitus in nonalcoholic fatty liver disease. |
| PubMedID- 22950055 | In addition, nafld is closely associated with metabolic syndrome, type 2 diabetes mellitus (t2dm) and cardiovascular morbidity and mortality. |
| PubMedID- 20625647 | Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors. |
| PubMedID- 25303488 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
| PubMedID- 23954219 | Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 23663765 | Conclusion: serum hscrp levels may be predictive of development of nafld in individuals with type 2 diabetes mellitus. |
| PubMedID- 26573192 | Objective: to investigate the effect of body mass index (bmi) on new-onset non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 22024083 | Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. |
| PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
| PubMedID- 24667697 | The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
| PubMedID- 24071688 | Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin. |
| PubMedID- 23653642 | nafld is strongly associated with obesity, dyslipidemia, type 2 diabetes mellitus, and cardiovascular disease. |
| PubMedID- 20353583 | This study aimed to examine the importance of serum endotoxin and inflammatory markers in non-alcoholic fatty liver disease (nafld) patients, with and without type 2 diabetes mellitus (t2dm), and to explore the effect of treatment with a lipase inhibitor, orlistat, on their inflammatory status. |
| PubMedID- 24062606 | There is a very high prevalence of nafld in individuals with type 2 diabetes mellitus. |
| PubMedID- 26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. |
| PubMedID- 24693952 | While nafld is closely associated with obesity, type 2 diabetes mellitus and coronary artery disease (cad), it may occur in the absence of type 2 diabetes and cad [6,7]. |
| PubMedID- 20627036 | Methods: this trial involved 51 patients of type 2 diabetes mellitus with nafld (g4 group), 50 patients of type 2 diabetes alone (g3 group), 45 patients of nafld alone (g2 group) and 42 healthy control subjects (g1 group). |
| PubMedID- 22927782 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. |
| PubMedID- 21886908 | type 2 diabetes mellitus-induced hyperglycemia in patients with nafld and normal lfts: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. |
| PubMedID- PMC4070608 | Nonalcoholic fatty liver disease (nafld) is closely associated with obesity, type 2 diabetes mellitus, dyslipidemia and hypertension, which form a cluster of metabolic disorders. |
| PubMedID- 22934189 | nafld is often associated with obesity, type 2 diabetes mellitus, and dyslipidemia and is also regarded as a hepatic manifestation of metabolic syndrome [4]. |
| PubMedID- 24505484 | Conclusions: our results provide the first demonstration of a positive and independent association between nafld and avs in patients with type 2 diabetes mellitus. |
| PubMedID- 26147768 | Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 22691891 | Aim: recent data have suggested that the presence of non-alcoholic fatty liver disease (nafld) in type 2 diabetes mellitus may also be linked to increased risk of cardiovascular disease (cvd) independent from metabolic syndrome. |
| PubMedID- 25243967 | [analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus]. |
| PubMedID- 24683323 | The occurrence of nafld in type 2 diabetes mellitus (t2dm) patients is reported to range from 50% to 75% [1, 2]. |
| PubMedID- 24901133 | Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 24919218 | [advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus]. |
| PubMedID- 23507799 | Therefore, nafld is strongly associated with type 2 diabetes mellitus and abdominal obesity. |
| PubMedID- 23843938 | Nonalcoholic fatty liver disease (nafld) is closely associated with type 2 diabetes mellitus. |
Page: 1